NVF webinar 16th of March 2022, 16:00 CET, Prof. dr. Rob Henning and Mohammed Saleh.
like to invite you to the next NVF meeting organized by the Dutch
Pharmacology Society. During this meeting you will have the chance to
participate in the lectures of Prof. dr.
R.H. (Rob) Henning and PhD candidate Mohamed Saleh.
16th of March
at 16:00-17:00 CET
Join Zoom Meeting
Meeting ID: 213 851 7914
1: Prof. dr. R.H. (Rob) Henning, Professor of
Pharmacology, Faculty of Medical Sciences, University of Groningen
Title: Hibernation inspired drug development.
Rob Henning explores the molecular mechanisms enabling the miracles of mammalian hibernation: a repetitive, rapid and reversible reduction of metabolism by over 90%, leading to a drop in body temperature close to freezing. Endogenous production of H2S takes center stage in protecting cells from damage during hibernation dictated swings in physiology. He will explain why hibernators inspired the team to search for allosteric modulators of cystathionine beta synthase (CBS) and how they approach the discovery of this new drug class.
2: PhD candidate Mohammed Saleh,
Leiden Academic Center for Drug Research
Saleh is a PhD candidate at Leiden Academic Center for Drug Research, working
under the supervision of Prof. Liesbeth de Lange and Dr. Jeroen
Elassaiss-Schaap. The focus of his PhD research is to develop mathematical
models to predict the pharmacokinetics of central nervous system in healthy and
of diseased conditions. Mohammed studied pharmacy in Egypt and did his master’s
in pharmaceutical sciences at Utrecht University. In between, he gained
experience on the drug industry at Novartis.
Title: LeiCNS-PK3.0: a
framework leveraging multiscale data for accurate brain PK predictions
of the unbound drug concentration in the central nervous system (CNS) is
crucial for drug development to evaluate efficacy of CNS drugs and the safety
of non-CNS drugs. Measuring the unbound drug concentration in the CNS target
sites, i.e. brain cells and the surrounding extracellular fluid (brain ECF), is
limited by ethical restriction of the human brain sampling, while lumbar
cerebrospinal fluid (CSF) has been shown to be an inaccurate surrogate of the
drug concentrations in the brain. The Leiden CNS pharmacokinetic predictor
(LeiCNS-PK3.0) is a physiologically based pharmacokinetic model that was
previously demonstrated to adequately predict the CNS PK profiles. LeiCNS-PK3.0
accounts mechanistically for the CNS physiology, a feature that allows
interpopulation and interspecies translations of the PK profiles. In this
webinar, we will explore the LeiCNS-PK3.0 model development and application to
predict the brain PK profiles in Alzheimer’s patients.